Jessica A. Hurt

Jessica A. Hurt

Auto-generated profile, based on publicly available information

Jessica A. Hurt

Biogen Inc, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2002 in Organic Letters
Verified
Journal Article
Closed access
AWAri J. Wassner
Ari J. Wassner
JHJessica A. Hurt
Jessica A. Hurt
JLJames D. Lear
James D. Lear
KAKarin Akerfeldt
Karin Akerfeldt

28 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAnna Axakova
Anna Axakova
MDMegan X Ding
Megan X Ding
ACAtina G. Cote
Atina G. Cote
RSRadha Subramaniam
Radha Subramaniam
VSVignesh Senguttuvan
Vignesh Senguttuvan
FRFrederick Roth
Frederick Roth
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease for which important subtypes are caused by variation in the Superoxide Dismutase 1 gene SOD1 . Diagnosis based on SOD1 sequencing can not only be definitive but also indicate specific therapies available for SOD1 -associated ALS (SOD1-ALS). Unfortunately, SOD1-ALS diagnosis is limited by the fact that a substantial fraction (currently 26%) of ClinVar SOD1 missense variants are classified as “variants of uncertain significance” (VUS). Although functional assays can provide strong evidence for clinical variant interpretation, SOD1 assay validation is challenging, given the current incomplete and controversial understanding of SOD1-ALS disease mechanism. Using saturation mutagenesis and multiplexed cell-based assays, we measured the functional impact of over two thousand SOD1 amino acid substitutions on both enzymatic function and protein abundance. The resulting ‘missense variant effect maps’ not only reflect prior biochemical knowledge of SOD1 but also provide sequence-structure-function insights. Importantly, our variant abundance assay can discriminate pathogenic missense variation and provides new evidence for 41% of missense variants that had been previously reported as VUS, offering the potential to identify additional patients who would benefit from therapy approved for SOD1-ALS.